Specifically, ERα can up-regulate the expression of MDM4 and MDM2 in some breast cancers and these effects can be blocked by endocrine therapy fulvestrant and tamoxifen (Swetzig et al., 2016). Here, MDM4 is linked to breast carcinoma.